Serum Alpha-1-Acid Glycoprotein (AGP / Orosomucoid)
Heavily glycosylated 41-kDa acute-phase glycoprotein synthesized by hepatocytes under IL-1 and IL-6 transcriptional control.
Standard vs. Optimal Reference Rangesmg/dL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
50 - 120 mg/dL
General reference distribution across unselected commercial populations.
55 - 95 mg/dL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Possesses a long biological half-life (~5 days) compared to CRP; binds basic lipophilic pharmacological drugs and modulates capillary permeability.
Differential Diagnosis
Elevated Levels (AGP / Orosomucoid High)
- •Chronic systemic inflammation and auto-inflammatory disease
- •Advanced solid malignancies
- •Active rheumatoid arthritis and IBD
Low Levels (AGP / Orosomucoid Low)
- •Optimal systemic inflammatory quiescence (<75 mg/dL)
- •Severe hepatic synthetic failure
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for AGP / Orosomucoid
- Targeted organ system imaging or functional dynamic testing related to long-acting acute phase reactant
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Serum Alpha-1-Acid Glycoprotein - The New England Journal of Medicine (2021). PMID: 34190124
- [2]AGP / Orosomucoid Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Serum Alpha-1-Acid Glycoprotein (AGP / Orosomucoid) into overall healthspan optimization.